ArticleBiology direct2026
Polydatin mitigates cigarette smoke-induced pulmonary apoptosis by regulating Bim via FoxO3 post-translational modifications and modulating the gut microenvironment.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCigarette smoke-mediated chronic pulmonary damage constitutes a critical predisposing factor for chronic obstructive pulmonary disease and lung cancer pathogenesis. Polydatin, a naturally occurring stilbenoid characterized by its potent anti-inflammatory and antioxidant properties, has yet to be fully elucidated regarding its protective role and the underlying molecular mechanisms in CSE-induced pulmonary injury.
methodsCigarette smoke extract (CSE)-induced lung injury murine models and MLE12 cells were treated with polydatin or other conditions. The investigation encompassed both intravital and extracorporeal modalities. Evaluations included pulmonary index, histopathology, oxidative stress markers, transcriptomic sequencing, protein expression (AKT/FoxO3/Bim), apoptosis (TUNEL), intestinal metabolomics, 16S rRNA microbiota profiling, and immunohistochemical staining of colon tissue.
resultsThe administration of polydatin dose-dependently in vivo alleviated CSE-induced systemic impairments including weight loss, pulmonary edema, and oxidative stress concurrently demonstrating high biocompatibility and low systemic toxicity. Furthermore, it modulates the intestinal microecology by depleting g__Pantoea and g__Enterococcus abundance, concurrently restoring mucosal barrier integrity via the enhancement of ZO-1 and Occludin levels. Mechanistic analysis demonstrated that polydatin directly interacts with AKT1 at the Thr308 residue, thereby reversing the CSE-induced attenuation of AKT1 and FoxO3 (Ser253) phosphorylation. This restoration facilitates the nuclear-to-cytoplasmic translocation of FoxO3 and subsequent downregulation of the pro-apoptotic protein Bim. This regulatory cascade effectively curtails apoptosis and DNA fragmentation, with a concomitant decrease in Bax and Cleaved-Caspase 3 expression.
conclusionsIn conclusion, polydatin exerts suitable protective effects against CSE-induced pulmonary injury by attenuating apoptosis through the AKT-FoxO3-Bim signaling cascade and simultaneously orchestrating the gut microenvironment. These findings highlight the potential of polydatin as a promising natural therapeutic agent for lung disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.